Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06021925
Other study ID # APHP221333
Secondary ID 2021-A01199-32
Status Recruiting
Phase
First received
Last updated
Start date December 13, 2023
Est. completion date June 13, 2024

Study information

Verified date January 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Xavier LAFARGE, Doctor
Phone 05 56 90 83 93
Email xavier.lafarge@efs.sante.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic histiocytic intervillositis (CHI) is associated with severe and recurrent obstetrical complications. A link between anti-HLA Antibodies (Ab) and CHI has recently been established. At the Etablissement Français du Sang (EFS), donors who have already given birth once and have high levels of anti-HLA are excluded from donating apheresis platelets and therapeutic plasma to prevent TRALI (Transfusion Related Acute Lung Injury). No studies have examined the obstetrical history of these donors. The question is: is there an association between anti-HLA levels and obstetrical complications?


Description:

Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of around 5 in 10,000 pregnancies. It is defined by major infiltration of the intervillous cavity by CD68+ maternal histiocytes, associated with fibrin deposition on the villous surface. CHI is associated with severe obstetrical complications and a very high recurrence rate, estimated at between 70% and 100%. These complications include early and late miscarriage, fetal death, severe growth retardation in surviving fetuses, and premature delivery. The survival rate reported in the literature varies between 30% and 50%. Anti-HLA antibodies are present in 54% of pregnant women at the end of pregnancy, and their rate increases towards the end of pregnancy. The presence of HLA antibodies also increases with the number of pregnancies, and is found in up to 74% of cases after more than 2 deliveries. The research question concerns the existence of a statistically significant association between the presence of high levels of anti-HLA antibodies and the occurrence of one or more obstetric complications.


Recruitment information / eligibility

Status Recruiting
Enrollment 6000
Est. completion date June 13, 2024
Est. primary completion date June 13, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female blood donors who have been tested for anti-HLA antibodies in the context of TRALI prevention between 2010 and 2020 at EFS Nouvelle Aquitaine [The donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well] - Women who have already given birth at least once (non-nulliparous women) - Women who have not expressed their opposition at the time of donation to participating in a research project and to be contacted Exclusion Criteria: - None [Donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well]

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Obstetrical history
Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.
Anti-HLA Antibody tests
Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.

Locations

Country Name City State
France Etablissement Français du Sang Nouvelle Aquitaine Bordeaux

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Etablissement Français du Sang (Nouvelle Aquitaine)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure the association between the occurrence of obstetrical complications and the level of anti-HLA Ab measured during the screening test performed by the EFS. Obstetrical complications are defined as (binomial qualitative variable) :
Preterm delivery < 37 WA
Fetal death in utero whatever the term
Early or late miscarriage
Early or late pre-eclampsia
Medical termination of pregnancy
Intrauterine growth retardation <3rd percentile
2 months
Secondary Type and precocity of obstetrical complication (multinomial qualitative variable) Preterm deliveries < 37 WA and = 34 WA
Premature deliveries < 34 WA
Fetal death in utero regardless of term
Late miscarriage < 22 WA and = 14 WA
Early miscarriage < 14 WA
Late pre-eclampsia > 37 WA and = 34 WA
Early pre-eclampsia < 34 WA
Medical termination of pregnancy
Intrauterine growth retardation <3rd percentile
2 months
Secondary Measure the association between the type and precocity of obstetrical complications according to the type of anti-HLA Ab (class I and/or class II), when these Ab are found during the screening test performed by the EFS Preterm deliveries < 37 WA and = 34 WA
Premature deliveries < 34 WA
Fetal death in utero regardless of term
Late miscarriage < 22 WA and = 14 WA
Early miscarriage < 14 WA
Late pre-eclampsia > 37 WA and = 34 WA
Early pre-eclampsia < 34 WA
Medical termination of pregnancy
Intrauterine growth retardation <3rd percentile
2 months
Secondary Verify the absence of response bias by comparing the HLA Ab levels of responding versus non-responding donors. Anti-HLA antibody rate (median) 2 months
See also
  Status Clinical Trial Phase
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005721 - Retaining Donors and Increasing Donation Frequency N/A
Recruiting NCT04078893 - The Effect of Recruiting Inactive Blood Donors Using Different Means N/A
Completed NCT02274064 - Motivating Type O- Blood Donors to Return N/A
Completed NCT04783077 - Community-Based Communication Approaches for Blood Donation in Ghana N/A
Completed NCT02717338 - Blood Donor Competence, Autonomy and Relatedness Enhancement Phase 3
Completed NCT01104740 - Dengue Seroprevalence Study in Blood Donors in the French West Indies
Completed NCT03988738 - Promoting Repeat Blood Donation Through Social Media Among First-time Donors in a Peruvian Blood Bank N/A
Completed NCT04088695 - Effect of a Web Page Based on a Motivational Video for Voluntary Blood Donation N/A
Completed NCT00005278 - Retrovirus Epidemiology Donor Study I (REDS I) N/A
Recruiting NCT00001846 - Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Completed NCT00005339 - Risk of Post Transfusion Hepatitis C Virus Infection N/A
Terminated NCT00005341 - Blood Donation--Immune Sequelae and Recruitment
Completed NCT03835299 - Addressing Fear and Risk of Vasovagal Reactions Among High School Donors N/A
Completed NCT00005360 - HIV Diversity and Pathogenesis in Donor-Recipient Clusters N/A
Completed NCT03102385 - A Survey of Attitudes of Experienced Blood Donors N/A
Completed NCT02145507 - Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution Phase 1
Completed NCT00029406 - Transfusion Infections Pediatric Prospective Study (TRIPPS) N/A
Completed NCT00006310 - KSHV Infection in Blood Donors From Texas N/A